The Journal of Clinical and Aesthetic Dermatology, 13 (12 Suppl 1), S29S33
Mechanisms of proton pump inhibitor-induced hypomagnesemia
Metabolism & Elimination Limited characterization of specific metabolic pathways has been published for both peptides: CJC-1295 (NO DAC): Peptidase-mediated degradation represents primary metabolic pathway Four amino acid substitutions provide enhanced resistance to dipeptidyl peptidase-IV Metabolites and degradation products not fully characterized in published literature Clearance from circulation within hours despite sustained pharmacodynamic effects Ipamorelin: Clearance of 0.078 L/h/kg in human pharmacokinetic studies Rapid elimination from plasma following distribution phase Metabolic pathways likely involve proteolytic cleavage at peptide bonds No significant accumulation observed with repeated dosing in animal models A notable pharmacokinetic-pharmacodynamic disconnect exists: despite relatively short plasma half-lives (30 minutes to 2 hours), growth hormone secretory effects persist for 6+ hours, suggesting either active metabolites, tissue retention, or persistent receptor signaling cascade activation
Whether you are located in Bend, Oregon, Seattle, Washington, or receiving care in California, Oregon, or Washington through telehealth, our team is available to help answer questions about your medication and treatment plan
